Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19

Laura Bergamaschi, Federica Mescia, Lorinda Turner, Aimee Hanson, Prasanti Kotagiri, Benjamin J. Dunmore, Hélène Ruffieux, Aloka De Sa, Oisín Huhn, Michael D Morgan, Pehuen Pereyra Gerber, Mark R. Wills, Stephen Baker, Fernando J Calero-Nieto, Rainer Doffinger, Gordon Dougan, Anne Elmer, Ian G Goodfellow, Ravindra K. Gupta, Myra Hosmillo, Kelvin Hunter, Nathalie Kingston, Paul J. Lehner, Nicholas J. Matheson, Jeremy K. Nicholson, Anna M. Petrunkina, Sylvia Richardson, Caroline Saunders, James E.D. Thaventhiran, Erik J. M. Toonen, Michael P. Weekes, Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, Berthold Göttgens, Mark Toshner, Christoph Hess, John R. Bradley, Paul A. Lyons, Kenneth G.C. Smith
doi: https://doi.org/10.1101/2021.01.11.20248765

Article Information

doi 
https://doi.org/10.1101/2021.01.11.20248765
History 
  • March 26, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Laura Bergamaschi1,2,19,
  2. Federica Mescia1,2,1,19,
  3. Lorinda Turner1,2,19,
  4. Aimee Hanson1,2,19,
  5. Prasanti Kotagiri1,2,19,
  6. Benjamin J. Dunmore2,
  7. Hélène Ruffieux3,
  8. Aloka De Sa1,2,
  9. Oisín Huhn2,
  10. Michael D Morgan4,5,
  11. Pehuen Pereyra Gerber1,2,
  12. Mark R. Wills1,2,
  13. Stephen Baker1,2,
  14. Fernando J Calero-Nieto5,
  15. Rainer Doffinger6,
  16. Gordon Dougan1,2,
  17. Anne Elmer7,
  18. Ian G Goodfellow8,
  19. Ravindra K. Gupta1,2,
  20. Myra Hosmillo8,
  21. Kelvin Hunter1,2,
  22. Nathalie Kingston9,10,
  23. Paul J. Lehner1,2,
  24. Nicholas J. Matheson1,2,11,
  25. Jeremy K. Nicholson12,
  26. Anna M. Petrunkina1,2,
  27. Sylvia Richardson3,
  28. Caroline Saunders7,
  29. James E.D. Thaventhiran1,2,13,
  30. Erik J. M. Toonen14,
  31. Michael P. Weekes1,
  32. Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration,
  33. Berthold Göttgens5,
  34. Mark Toshner2,15,16,
  35. Christoph Hess1,2,17,18,
  36. John R. Bradley2,10,
  37. Paul A. Lyons*,1,2 and
  38. Kenneth G.C. Smith*,1,2
  1. 1Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK
  2. 2Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
  3. 3MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
  4. 4Cancer Research UK – Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK
  5. 5Department of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK
  6. 6Department of Clinical Biochemistry and Immunology, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
  7. 7Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
  8. 8Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
  9. 9Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
  10. 10NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
  11. 11NHS Blood and Transplant, Cambridge, UK
  12. 12The Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Murdoch, Western Australia WA 6150, Australia
  13. 13MRC Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge CB2 1QR, UK
  14. 14R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands
  15. 15Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
  16. 16Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
  17. 17Department of Biomedicine, University and University Hospital Basel, 4031Basel, Switzerland
  18. 18Botnar Research Centre for Child Health (BRCCH) University Basel & ETH Zurich, 4058 Basel, Switzerland
  1. ↵*Correspondence: pal34{at}cam.ac.uk (PAL) or kgcs2{at}cam.ac.uk (KGCS)
    1. 1Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK
    2. 2Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    3. 3MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
    4. 4Department of Clinical Biochemistry and Immunology, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    5. 5Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    6. 6Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    7. 7Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
    8. 8NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
    9. 9Australian National Phenome Centre, Murdoch University, Murdoch, Western Australia WA 6150, Australia
    10. 10Department of Clinical Biochemistry and Immunology, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    11. 11MRC Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge CB2 1QR, UK
    12. 12R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands
    13. 13Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
    14. 14Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
    15. 15Department of Biomedicine, University and University Hospital Basel, 4031Basel, Switzerland
    16. 16Botnar Research Centre for Child Health (BRCCH) University Basel & ETH Zurich, 4058 Basel, Switzerland
    17. 18Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    18. 19Department of Veterinary Medicine, Madingley Road, Cambridge, CB3 0ES, UK
    19. 20Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK
    20. 21Cancer Research UK, Cambridge Institute, University of Cambridge CB2 0RE, UK
    21. 22Department of Obstetrics & Gynaecology, The Rosie Maternity Hospital, Robinson Way, Cambridge CB2 0SW, UK
    22. 23Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA, Australia
    23. 24Cambridge and Peterborough Foundation Trust, Fulbourn Hospital, Fulbourn, Cambridge CB21 5EF, UK
    24. 25Department of Surgery, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    25. 26Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK
    26. 27Centre of Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, WA 6150, Australia
    27. 28Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
    28. 29Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge, Cambridge CB2 0AH, UK
    29. 30Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
    30. 31Department of Paediatrics, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
    31. 32Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
    32. 33European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK
    33. 34Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK

    1. ↵19 These authors contributed equally

    2. 17 These authors contributed equally

    Back to top
    Posted March 26, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email
    Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19
    Laura Bergamaschi, Federica Mescia, Lorinda Turner, Aimee Hanson, Prasanti Kotagiri, Benjamin J. Dunmore, Hélène Ruffieux, Aloka De Sa, Oisín Huhn, Michael D Morgan, Pehuen Pereyra Gerber, Mark R. Wills, Stephen Baker, Fernando J Calero-Nieto, Rainer Doffinger, Gordon Dougan, Anne Elmer, Ian G Goodfellow, Ravindra K. Gupta, Myra Hosmillo, Kelvin Hunter, Nathalie Kingston, Paul J. Lehner, Nicholas J. Matheson, Jeremy K. Nicholson, Anna M. Petrunkina, Sylvia Richardson, Caroline Saunders, James E.D. Thaventhiran, Erik J. M. Toonen, Michael P. Weekes, Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, Berthold Göttgens, Mark Toshner, Christoph Hess, John R. Bradley, Paul A. Lyons, Kenneth G.C. Smith
    medRxiv 2021.01.11.20248765; doi: https://doi.org/10.1101/2021.01.11.20248765
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools

    Subject Area